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Abstract
Objective: Limited data regarding adrenal involvement in multiple endocrine neoplasia type 1 (MEN1) is
available. We describe the characteristics of MEN1-associated adrenal lesions in a large cohort to
provide a rationale for their management.
Methods: Analysis of records from 715 MEN1 patients from a multicentre database between 1956
and 2008. Adrenal lesions were compared with those from a multicentre cohort of 144 patients with
adrenal sporadic incidentalomas.
Results: Adrenal enlargement was reported in 20.4% (146/715) of patients. Adrenal tumours
(O10 mm in size) accounted for 58.1% of these cases (10.1% of the whole patient cohort). Tumours
were bilateral andO40 mm in size in 12.5 and 19.4% of cases respectively. Hormonal hypersecretion
was restricted to patients with tumours and occurred in 15.3% of them. Compared with
incidentalomas, MEN1-related tumours exhibited more cases of primary hyperaldosteronism, fewer
pheochromocytomas and more adrenocortical carcinomas (ACCs; 13.8 vs 1.3%). Ten ACCs occurred
in eight patients. Interestingly, ACCs occurred after several years of follow-up of small adrenal tumours
in two of the eight affected patients. Nine of the ten ACCs were classified as stage I or II according to the
European Network for the Study of Adrenal Tumors. No evident genotype/phenotype correlation was
found for the occurrence of adrenal lesions, endocrine hypersecretion or ACC.
Conclusions: Adrenal pathology in MEN1 differs from that observed in sporadic incidentalomas. In the
absence of relevant symptoms, endocrine biology can be restricted to patients with adrenal tumours
and should focus on steroid secretion including the aldosterone–renin system. MEN1 is a high-risk
condition for the occurrence of ACCs. It should be considered regardless of the size of the tumour.
European Journal of Endocrinology 166 269–279
Introduction
Multiple endocrine neoplasia type 1 (MEN1) is an
autosomal dominant hereditary syndrome caused by
germline mutations of the menin gene that predisposes
the development of endocrine and non-endocrine
tumours with variable penetrance (1–3). The most
frequent MEN1 features are primary hyperparathyroid-
ism, pancreatic endocrine tumours (PETs) and pituitary
adenomas (4). Adrenal enlargement and tumours
related to MEN1 have been reported as early as 1960
(5). Its prevalence varies from 9 to 73% depending on
series, radiological methods and criteria used to
characterise adrenal enlargement (6–11). Three key
issues with potential practical implications regarding
adrenal involvement in MEN1 are: i) whether or not
biological investigation of adrenal function should be
performed in all patients to detect endocrine hypersecre-
tion; ii) whether MEN1 predisposes the development of
adrenocortical carcinomas (ACCs) and, if so, is a specific
European Journal of Endocrinology (2012) 166 269–279 ISSN 0804-4643
q 2012 European Society of Endocrinology DOI: 10.1530/EJE-11-0679
Online version via www.eje-online.org
AUTHOR COPY ONLY
follow-up required; and iii) is there any genotype–
phenotype correlation that suggests the need to focus
on the adrenal morphology and function of a subset of
meninmutation-affected carriers. Data published on the
prevalence of endocrine dysfunction and the occurrence
of ACC are controversial: while the majority of adrenal
tumours have been reported as non-hyperfunctioning, a
22% prevalence of hypersecreting lesions has been
found in one study (10, 11, 12, 13). Similarly, no cases
of ACC were identified in some series despite several
years of follow-up contrasting with a 6% prevalence
found in two series (5, 8, 12). Discrepant conclusions
have also been published for genotype–phenotype
relationships since the seminal finding that adrenal
lesions were preferentially associated with mutations in
exons 2 and 10 has not been confirmed (8, 11).
Altogether, our limited knowledge concerning these
keys issues prevented the establishment of a consensus
for their management (13). Sample variability may be
responsible for these discrepant results and the size of
cohorts studied is a critical point to assess the
prevalence and characteristics of rare endocrine and
neoplastic events in a rare disease. Importantly, all
information available to date on adrenal involvement in
MEN1 are drawn from small cohorts with a median of
34 patients studied (6, 7, 14, 15). The aim of this study
was to provide information from a large cohort that
may serve to establish a rationale for the clinical
management of MEN1-associated adrenal lesions. For
this purpose, we analysed the multicentre database of
the ‘Groupe d’e´tude des Tumeurs Endocrines’ (GTE)
involving 715 MEN1 patients and compared the
findings observed with that of 144 patients with
sporadic adrenal incidentalomas.
Patients and methods
Patients and epidemiological methods
The GTE network for MEN1, created in February 1991,
includes clinical centres that are scattered in 22 regions
of France and Belgium, and associated with four genetic
departments in charge of the diagnosis. Data from
MEN1 patients who were prospectively followed from
1956 to 1991 in the various clinical departments
involved in the management of MEN1 patients were
incorporated into the GTE database in 1991. Since
1991, GTE members have been required to declare new
cases for inclusion in the national MEN1 database.
Moreover, the genetic departments regularly detect
new cases and family trees are established for all
familial cases. They are also used to identify affected
family members.
To be included, patients had to fulfil specific diagnosis
criteria according to International Guidelines (13, 16):
i) patients with a MEN1 mutation and presenting at
least one of the following symptomatic or silent lesions:
primary hyperparathyroidism, pancreatic or duodenal
endocrine tumour, pituitary tumour, adrenal tumour,
thymic neuroendocrine tumour bronchial neuroendo-
crine tumour or gastric enterochromaffin-like tumour
(ECLoma); ii) patients belonging to an already known
MEN1 family (at least one first-degree relative affected)
and presenting at least one of the aforementioned
lesions; and iii) patients without positive genetic testing
or family background presenting at least two of the
three major MEN1 lesions, i.e. primary hyperparathyr-
oidism, pancreatic or duodenal endocrine tumour, or
pituitary adenoma. They were considered with caution
and selected after a critical case-by-case analysis
following rules already published by the GTE group
(17). The ‘first lesion’ corresponds to the lesion that was
discovered first, whatever the other possible MEN1-
associated lesions discovered during the following days
or weeks. The patient’s age at the onset of a clinical
feature is the age at the time of diagnosis for this feature.
A patient was considered to have a family history of
MEN1 when another MEN1 case was discovered or
highly suspected in the same family during the pre-
diagnosis period. The referent physician provided initial
data for the patient. A copy of each patient’s file was
obtained and stored in the Department of Epidemiology
at the Burgundy School of Medicine. A computerised
recording file (CRF) was created and filled in. This CRF
comprised the following sections: identification data,
pancreas gland, parathyroid glands, pituitary gland,
adrenal glands, other endocrine tumours, thyroid,
associated diseases, genetics and follow-up. For each
lesion, the date of occurrence, biochemical and
morphological tests, treatments and pathological
reports were noted and then recorded in a computerised
file. From copies of the patients’ medical files, infor-
mation was collected on a regular basis and data were
updated. According to International Guidelines,
patients should be followed up on a regular yearly
basis (16). When adrenal involvement was mentioned
and/or informative data were missing an additional
query form was sent to the physician in charge of the
patient. The main centres were regularly visited by the
surgeon in charge of the database (P Goudet).
For comparison purpose, a retrospective cohort of
patients with sporadic adrenal incidentalomas was
established. In accordance with guidelines of the French
Society of Endocrinology, only incidentalomasO10 mm
in size deserved further investigation (18). The six main
endocrine departments of the GTE network contributing
to the present series were asked to provide 144 cases of
patients with adrenal incidentalomas randomly selected
among cases explored during the 2002–2008 period.
No control subject had MEN1 mutation testing.
However, no patient had any other endocrine lesions
except the adrenal tumour at the time of diagnosis or
during the follow-up period, and had no family history
of MEN1.




The type and size of adrenal lesions reported correspond
to the evaluation made by radiologists in each centre.
Only magnetic resonance imaging (MRI) and computed
tomography (CT) scanning results were taken into
consideration. Classification of adrenal lesions was
performed according to initial radiologist reports. We
arbitrarily classified adrenal lesions into two groups:
adrenal hypertrophy for non-nodular enlargement
or nodules !10 mm in size and tumours for nodules
O10 mm in size. For analysis of follow-up records,
tumour progression was arbitrarily considered signi-
ficant when the largest diameter of the lesion increased
by at least 10 mm.
Endocrine investigations
Diagnosis of non-secreting adrenal lesion was based on
normal biological endocrine evaluations conducted in
reference laboratories among the GTE network coupled
with variable commercially available assays. A full set of
analyses was considered mandatory to establish the
secretory status and included: 24 h urinary free cortisol
(UFC) and/or 1 mg dexamethasone suppression test;
plasma ACTH concentration; 24 h urinary excretion of
metanephrines or free catecholamines; plasma total
testosterone and DHEA-S concentration; aldosterone
concentration; and renin or plasma renin activity
(PRA). Patients lacking more than one of these
investigations were not included in the analysis of
functionality of adrenal lesions. ACTH-independent
Cushing’s syndrome was established by the presence
of clinical features, increased UFC or lack of dexametha-
sone suppression associated with suppressed plasma
ACTH levels. Primary hyperaldosteronism was estab-
lished in the presence of elevated urinary or plasma
aldosterone concentrations associated with suppressed
PRA or plasma renin concentrations.
MEN1 gene analysis
Exons 2–10 of the MEN1 gene were amplified from the
genomic DNA of the patients’ blood lymphocytes by
PCR using a set of specific primers, as described in a
previous study (19). The sequencing reactions
were performed directly from PCR-amplified DNA on
automated sequencers (ABI 377, Applied Biosystems).
A MEN1 cDNA partial sequence was produced by
RT-PCR with forward and reverse primers at position
340 and 1325 respectively. This was used to search for
MEN1 locus large rearrangements and/or deletions
using Southern blot and FITC-labelled cDNA probes for
fluorescence in situ hybridisation on metaphase kar-
yotypes produced from in vitro Epstein–Barr virus
immortalised lymphocytes of patients with MEN1.
When no mutations were found, we concluded that
further studies were needed on the menin locus to find
small intragenic deletions or complex inactivation
pathways of the 5 0 promoting sequences of the MEN1
locus, which has been recently identified (20).
Classification of adrenal lesions
Removed adrenal tissues were analysed using conven-
tional histopathological procedures includingWeiss score
(21).WhenACC tissuewas available a secondWeiss score
determinationwas performed.AWeiss scoreR3has been
associatedwith a significant increase in the riskof tumour
recurrence after surgery and was therefore considered as
consistent with the diagnosis of ACC (22, 23). The
staging of ACCs was performed prospectively or retro-
spectively according to the European Network for the
Study of Adrenal Tumors (ENS@T) classification based
on pre- and peri-operative findings (24).
Statistical methods
Results are expressed as meanGS.D. For quantitative
data, comparisons were made by the t-test. For
qualitative data, comparisons between the groups
were based on the c2 test.
Results
Control group of sporadic adrenal
incidentalomas
The patients’ age and sex ratios were 55G0.9 years and
60 females/84 males respectively. One hundred and
fifty-five adrenal tumours were found in the 144
patients with a mean size of 31 mm (range: 10–160).
The overall prevalence of adrenal hyperactivity was
6.6%. No case of primary hyperaldosteronism was
identified. Unequivocal Cushing’s syndrome and pheo-
chromocytomas were found in 0.7% (1/144) and 5.5%
(8/144) of patients respectively. Two ACCs were
diagnosed (1.3% prevalence): a 150 mm left adrenal
tumour (Weiss score: 4) associated with a lung
metastasis occurred in a 44-year-old female who died
7 months later; and a 100 mm left adrenal tumour
(Weiss score: 5) was found in a 39-year-old woman who
was operated on and maintained on mitotane for 3
years.
Clinical presentation in MEN1
One hundred and eighty-six adrenal lesions occurring
in 146 patients (84 females and 62 males) were
reported (20.4% of the whole series, Fig. 1). The mean
age at diagnosis of adrenal lesions was 46.1G1.4 years
and ranged from 2 to 78 years. The age at which
adrenal tumours (e.g. lesions O10 mm in size) were
identified was significantly younger than in patients
with sporadic incidentalomas (P!0.05) but sex ratios
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were similar between the groups. Adrenal lesion or the
resulting endocrine syndrome was the first reported
symptom of MEN1 in only 6% of cases. It was diagnosed
concomitantly or after the diagnosis of MEN1 in 33 and
61% of cases respectively. Clinical symptoms of adrenal
hyperfunction or abdominal pain revealed lesions in
only 11% of patients and most were identified during
systematic abdominal imaging for MEN1 (Fig. 2).
Primary hyperparathyroidism, PETs and pituitary
adenomas were reported in 93.1, 70.1 and 44.4% of
MEN1 patients with adrenal involvement respectively.
Among the PETs, there were 56 gastrinomas, 16
insulinomas, two somatostatinomas and 61 apparently
non-functioning PETs. Apparently, non-functioning
PETs and gastrinomas were the more frequent subtypes
of PETs and occurred in 59.8 and 54.9% respectively.
The prevalence of these main MEN1-related tumours
was not different from that found in patients without
adrenal involvement.
Adrenal imaging at diagnosis
The characterisation of adrenal lesions at MRI or CT
scanning was available is 124/186 lesions (Fig. 3). It
ranged from slight enlargement to tumours of 120 mm
in size. Adrenal tumours were found in 72 of the 124
(58.1%) patients reported with adrenal involvement
corresponding to 10.0% (72/715) of the overall cohort.
A total of 19.4% of the tumours were below 40 mm in
size. The mean size of MEN1-associated tumours did not
differ from that observed in incidentalomas. Of the 72
patients with adrenal tumours, 12.5% had bilateral
lesions. This prevalence was not different from the 7.3%
prevalence found in incidental tumours (PZ0.24). The
prevalence of declared adrenal lesions was similar
before and after 1991 and 1998, these periods
corresponding to the development of the spiral CT
scan and the multidetector CT scan respectively.
Functionality of adrenal lesions
Seventy-three of the 146 MEN1 patients with radio-
logical adrenal involvement underwent the biochemical
evaluation required to characterise the functional
status of adrenal lesions. Normal although incomplete
endocrine evaluation was reported in 18.5% of patients
while 31.5% of the 146 patients had no biological
information available. None of these patients had
clinical evidence of adrenal hypersecretion.
Eleven patients (7.5%) with radiological adrenal
involvement had documented endocrine hypersecre-
tion. These 11 patients had adrenal tumours and no
case of endocrine hypersecretion was documented in
patients that only had adrenal hypertrophy. The overall
prevalence of endocrine hypersecretion among MEN1
patients with adrenal tumours was 15.3% (11/72) and
was significantly increased compared with the 6.9%
(10/144) prevalence found in adrenal incidentalomas
(PZ0.03). Four cases of primary hyperaldosteronism
were found among MEN1 patients (Table 1). Case no. 2
in which tumoural DNA analysis after surgical excision
revealed loss of heterozygosity for polymorphic chromo-
some 11 DNA markers, including those in the region of
the MEN1 locus, has been previously published (25).
ACTH-independent Cushing’s syndrome was diagnosed
in four cases (Table 2). Two patients had clinical and
biological hyperandrogenia that revealed an ACC (see
below). One case of bilateral pheochromocytoma was
reported in a patient with primary hyperparathyroidism
and PET, hyperparathyroidism, acromegaly and familial
cases of MEN1. However, no genetic analysis was
performed and the patient also had obvious clinical
features of neurofibromatosis type 1. The frequency of
primary hyperaldosteronism and overt ACTH-independent
Cushing’s syndrome was significantly increased in
MEN1 patients with adrenal tumours compared with
patients with sporadic incidentalomas (P!0.05). On
the contrary, the prevalence of pheochromocytoma was
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CT scan characterisation = 124
Adrenal enlargement
(< 1 cm) n = 52/124
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Figure 2 Circumstances of diagnosis of the adrenal lesions inMEN1
patients. The results are expressed in percentage of patients.




Forty-five MEN1 patients underwent resection of
adrenal tumours. Benign cortical adenomas and/or
hyperplasia were diagnosed in 35 cases and two cases of
adrenal metastases of a somatostatinoma and a
gastrinoma were identified. Ten ACCs were diagnosed
in eight patients (1.4% of the whole cohort; see Table 3).
The prevalence of ACC in MEN1 patients with adrenal
tumours was significantly higher than in patients
with adrenal incidentalomas (13.8 vs 1.3%, P!0.05).
Three MEN1 patients with ACC had no related clinical
or biological abnormality, two complained of abdominal
or dorsal pain and three patients had clinical mani-
festations of endocrine hypersecretion (Table 3). Several
features of ACCs deserve particular attention. First, five
of the ten ACCs had a small size!50 mm at diagnosis
and nine of the ten ACCs displayed ENS@T stage I or II
allowing apparently complete surgical resection in all
but one case. Consequently, six of the eight patients
were alive after 2–36 years of follow-up. Secondly, one
patient (no. 5) had bilateral ACCs and one patient (no.
8) was diagnosed as having two distinct small-sized
ACCs within the same adrenal gland after careful
examination by two independent referent pathologists.
Thirdly, ACCs developed during the follow-up of
relatively small adrenal nodules in two patients. In the
first patient (no. 8), two nodules of 8 and 13 mm on the
right gland were discovered at the age of 21 years.
Unenhanced attenuation values were both 38 UH. Five
years later an increase in size of the two right adrenal
lesions to 29 and 30 mm prompted to proceed with
surgery and identification of two distinct ACCs.
A 25 mm calcified adrenal lesion with an unenhanced
attenuation of 40 UH was identified in patient no. 7 at
initial evaluation. After 4 years of follow-up, the tumour
size had increased to 40 mm. After surgical excision,
two independent expert pathologists concluded to a rare
case of adrenocortical sarcomatoid carcinoma. Of note,
this patient had a history of gastro-intestinal stromal
tumour as reported earlier (26). Fourthly, another
noteworthy observation is the occurrence of ACC in a
3-year-old patient.
Genetics
No genotype–phenotype correlation was evident for the
occurrence of adrenal lesions, adrenal tumours and



























Figure 3 Size of adrenal lesions in MEN1 patients. The size is
divided into three categories and results are expressed in
percentage of lesions in each category.


















































































M, male; F, female; PA, plasma aldosterone; PR, plasma renin; PRA, PR activity; PET, pancreatic endocrine tumour; LOH, loss of heterozygosity.
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Specifically, there was no statistical difference for the
occurrence of adrenal lesions between patients with
germline mutations in exons 2 and 10 and those with
mutations in other exons in the menin gene.
Follow-up
Records of follow-up were available for 53 patients with
adrenal lesions for a mean duration of 7.4G0.8 (3–72)
months. During follow-up, 13 of the 53 patients
(24.5%) showed a significant increase in size of the
adrenal lesion and two (4%) developed a contralateral
lesion of more than 10 mm in size. As mentioned above,
three ACCs were identified in two patients at patho-
logical examination of adrenal nodules that increased in
size after 4 and 8 years of follow-up.
Discussion
This study analyses the findings observed in a multi-
centre database involving 715 MEN1 patients and
compares it with those found in a multicentre control
cohort of 155 sporadic adrenal incidentalomas. There-
fore, this is the largest study on adrenal involvement in
MEN1. Since cases originate from 22 areas of France and
from Belgium, one would expect a reduced selection bias
comparedwithmonocentric reports (5, 8, 9, 10, 11, 12).
As previously reported, clinical symptoms of adrenal
hyperfunction or abdominal pain seldom revealed the
adrenal lesions and systematic abdominal imaging
contributed to the diagnosis in 89% of MEN1 patients
(6, 11, 15). The prevalence of declared adrenal
enlargement in our large series was 20.3% and
unilateral in the majority of cases. As found in the few
series giving enough detail on the size of adrenal lesions
(6, 7, 11), only half of declared lesions were adrenal
tumours O10 mm in size (10% prevalence in our
series). One weakness of the study is the fact that
imaging was heterogeneous as to technique and
radiological equipment, since the study covers a
40-year span, and was not submitted to central review.
Underestimation of slight enlargement or small nodules
of the adrenal glands is therefore plausible and could
explain the differences with series acknowledging a
prevalence of adrenal enlargement between 35 and
55% (5, 9, 11, 12, 14). Indeed, one of the three adrenal
lesions identified by endoscopic ultrasound sonography
(EUS) may be missed by CT (11) and, in a recent study
using exclusively EUS, up to 73% of MEN1 patients had
evidence of adrenal enlargement. The pathological/
clinical significance of mild adrenal enlargement in
MEN1 patients is unknown but, similarly to what has
been described in sporadic and asymptomatic inciden-
talomas (27), no case of adrenal enlargement below
10 mm was associated with endocrine dysfunction or
evolution towards ACC.
Fifteen per cent of the 73 (11/73) patients in whom
hormonal workup was performed had evidence of
adrenal hyperactivity. This prevalence is increased
compared with the 0–6% prevalence of adrenal
hypersecretion usually quoted in the literature (5, 9,
12, 14). It is noteworthy that only a minority of
published series included a detailed hormonal evalu-
ation and thus underestimation of adrenal hyperactivity
in previous studies may be hypothesised. We cannot
exclude that the prevalence of pheochromocytoma
could be underestimated since accurate biological
diagnostic tools were probably lacking in the early
years of the registry. On the contrary, overestimation of
the prevalence of endocrine hypersecretion in our series
is probable since 50% of patients with adrenal lesions
who were clinically asymptomatic from an endocrine
perspective did not undergo a complete biological
evaluation and therefore were not included in the
prevalence calculation. Of note, all patients in our series















1 37 M 24 h UFC: 130 mg (n!91) 30/L PHPT Deletion exon 4 Not available Lost to follow-up
Undetectable plasma ACTH Macroprolactinoma
PET





Deletion exon 4 Benign adenoma Corticotroph insuffi-
ciency for 11 months




Not performed Not available Death from respiratory
insufficiency before
surgery
4 69 M 24 h UFC: 163 mg (n!100)
Undetectable plasma ACTH




Deletion exon 3 Benign adenoma Death soon after
surgery from
metastatic PET
PET, pancreatic endocrine tumour; PHPT, primary hyperparathyroidism; M, male; F, female; UFC, urinary free cortisol; DST, dexamethasone suppression
test; L, left; R, right.
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II/4 Apparent complete surgical
excision
Maintained on mitotane
Development of liver metastasis
Death 3 years after the diag-
nosis despite chemotherapy





Death in the month after surgery







I/3&5 Apparent complete surgical
excision
Mitotane stopped because of
adverse effects
3.5 years, alive




II/3 Apparent complete surgical
excision
Development of benign
contralateral tumour (10 mm)
14 years, alive

















I/3&5 Apparent complete surgical
excision
Left adrenalectomy 1 year later
for benign adenoma
3 years, alive
M, male; F, female; NS, non-secreting; NA, not available; L, left; R, right; UK, unknown; PHPT, primary hyperparathyroidism; PET, pancreatic endocrine tumour; IE, initial evaluation; PRA, plasma renin activity;
























































with adrenal hypersecretion had adrenal tumours and
no case of endocrine hypersecretion was documented in
patients that only displayed adrenal hypertrophy.
Altogether our data confirm that most of MEN1-
associated lesions are hormonally silent and suggest
that, in the absence of evocative clinical features,
endocrine investigations should be restricted to patients
with tumours O10 mm in size.
Adrenal hyperfunction included primary hyperaldos-
teronism (nZ4), Cushing’s syndrome (nZ4), excessive
androgen secretion (nZ2) and pheochromocytoma
(nZ1). Primary hyperaldosteronism in the setting of
MEN1 has seldom been described, usually as isolated
case reports (25), and was unusually frequent in this
series. This discrepancy with previous reports might be
related to the difficulty in diagnosing primary hyper-
aldosteronism spontaneously (28) or in patients that
are, in our practice, often already treated with
antihypertensive agents that interfere with the evalu-
ation of the renin–aldosterone system and may mask
hypokalemia. Evaluation of the renin–aldosterone
system may also have been overlooked in some series
(5, 6, 11, 12). In addition, the prevalence of primary
aldosteronism was significantly increased compared
with the expected low prevalence that we found in
sporadic incidentalomas (29). Another point of import-
ance is that primary hyperaldosteronism was predomi-
nantly related to unilateral lesions, potentially curable
with surgery, and not to bilateral hyperplasia with the
limits of statistical comparison of small numbers. These
findings suggest that aldosterone-producing adenomas
could be a more common component of the MEN1
adrenal phenotype than previously thought and that
caution should be paid to the renin–aldosterone system
evaluation in hypertensive patients with MEN1.
ACTH-independent Cushing’s syndrome was found in
2.7% of patients with adrenal enlargement and 5.5% of
patients with adrenal tumours. Interestingly, Cushing’s
syndrome was due to a unilateral disease in three of the
four of our cases with a frank asymmetry in size in
favour of the adenoma allowing unilateral adrenalect-
omy. The prevalence of Cushing’s syndrome in our series
was increased compared with that found in sporadic
incidentalomas. The 1% prevalence found in our control
group was significantly lower to that quoted in series of
the literature with a calculated median of 7.9% in a
2003 review (30). However, in the overwhelming
majority of published series, patients do not display
overt Cushing’s syndrome but are diagnosed as having
‘subclinical’ Cushing’s syndrome, e.g. poorly active
adenomas associated with mild and often dissociated
biological abnormalities of the hypothalamus-pituitary-
adrenal (HPA) axis (18, 30). Owing to the lack of
uniformity in the endocrine investigations between
centres and the absence of consensus on diagnostic
criteria, the diagnosis of subclinical Cushing’s syndrome
was not considered in the MEN1 and sporadic
incidentalomas groups (31, 32, 33). At variance with
the expected 5% prevalence of pheochromocytoma in
sporadic incidentalomas (18, 34, 35), only one MEN1
patient had a bilateral pheochromocytoma but the
responsibility of the menin dysfunction cannot be
established since this patient had clinically obvious
neurofibromatosis type 1. Fewer than 10 cases of
pheochromocytoma in MEN1 patients have been
reported (2, 8, 9, 36, 37). In cases where DNA testing
was performed, patients were found to have germline
MEN1 mutations, as well as loss of heterozygosity
around the MEN1 gene in the pheochromocytoma
tumour tissue (38). These findings associated with the
development of bilateral pheochromocytomas in some
genetically engineered mice models of MEN1 (39)
suggest that pheochromocytoma is part of the MEN1
syndrome. However, our data issued from a very large
cohort together with data from the literature suggest
that the occurrence of pheochromocytoma in patients
with MEN1 is a very rare event.
Lastly, hyperandrogenism due to an excessive
secretion of androgens, an almost specific feature of
malignant adrenal secreting tumours (31), revealed an
ACC in two cases.
Two credits of our study are to highlight the
epidemiology of ACCs with the statistical power
provided by a large cohort and to provide additional
information on ACCs that is almost always lacking in
the literature (CT scanning details, staging, Weiss score
and survival). The overall prevalence that we found
(1.4% of the whole MEN1 population) is in accordance
with the 0–6% prevalence found in other series of the
literature. However, this prevalence reached 13.8% in
patients with adrenal tumours. Such prevalence
significantly exceeded the 1.3% prevalence of ACC
found in our control series, which is concordant with
that found in a recent review and meta-analysis of
sporadic adrenal incidentalomas (29). Another import-
ant finding is that three of the ten ACCs were identified
after growth of small adrenal tumours. This scenario
has already been described in MEN1 (8, 9, 11) but is
hardly ever encountered in follow-up series of adrenal
incidentalomas (18). Interestingly, elevated spon-
taneous CT attenuation values at previous evaluations
before spontaneous increase in size were not consistent
with benign, lipid-rich adenomas (18, 35, 41). The
occurrence of growth after 4–8 years of follow-up may
suggest that these were slowly growing ACCs. Another
important finding is that nine of the ten ACCs were
classified ENS@T stage I or II allowing apparently
complete surgical resection in all but one case, an
unexpected feature in sporadic ACCs (31, 42). Else-
where, the Weiss score was %4 in four of the seven
ACCs in which it was available. The stage of ACCs as
well as theWeiss score are important prognostics factors
for ACC (42). Our findings suggest that MEN1-related
ACCs may represent a specific entity with reduced
aggressiveness compared with sporadic ACCs. However,
this hypothesis should not eclipse the fact that, as others
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reported in the literature, two patients of our series died
of their ACCs (8, 11, 43). An alternative explanation for
our findings is that programmed imaging studies in the
abdominal workup of MEN1may have helped to identify
ACCs at an early stage.
Altogether our observations combined with the
demonstration of LOH at 11q13 in most MEN1-related
ACCs analysed (9, 10), and the occurrence of ACCs in
mouse models of MEN1 (39), strongly suggest that the
loss of the antioncogenic menin protein constitutes a
predisposing condition for the development of adrenal
malignancy that may develop after the occurrence of
another somatic genetic event (2, 4, 40).
The pathogenesis of MEN1-associated adrenal
lesions has been questioned and the hypothesis of a
stimulating role of growth factors and peptides secreted
by PET on adrenal tumorigenesis has been debated (5, 9,
11, 14). This issue was outside the scope of our clinical
study but it should be noted that there was no evidence of
PET in w30% of patients of our series with adrenal
involvement. However, and as discussed earlier, we
found a number of differences between sporadic inciden-
talomas and MEN1 tumours suggesting that they
represent two different entities. Unfortunately, we were
not able to find any clear genotype/phenotype correlation
for the occurrence of adrenal tumours, hypersecreting
lesions or ACCs that could be of help to focus
investigations and follow-upona subset ofMEN1patients.
Previous attempts to identify genotype/phenotype corre-
lation for differentMEN1-related tumours have been so far
disappointing (4).
Conclusions
Altogether our study suggests that, similarly to what has
been described in adrenal incidentalomas, slight enlarge-
ment is usually exempt of clinical relevance and no
additional endocrine investigation is needed if there is no
clinical suspicion of endocrine hyperactivity. On the
contrary, a MEN1-associated adrenal tumour differs in
many ways from sporadic incidental adrenal tumours. In
MEN1, endocrine investigations should focus on steroid
hormone secretion since pheochromocytoma appears to
be extremely rare and attention should be paid to the
investigation of the aldosterone–renin system. Although
rare, the occurrence of ACC should also be considered in
all patients with adrenal tumours lacking CT charac-
teristics of benign cortical adenoma even if their size is
below 40 mm. Finally, lifelong imaging of adrenal
tumours should be part of the follow-up agenda of
patients with MEN1 as has been recommended for PET.
The precise frequency of these examinations has to be
determined. A significant increase in size of adrenal
lesions eventually associated with a change in spon-
taneous attenuation values at CT scanning or lipid
content at MRI should prompt towards surgery.
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